06 Nov CRAC Montreal: Medical use of Cannabis in Canada
CRAC talks Montreal: Thursday, December 8, 2016
Hot topic not to miss: Medical Cannabis and Clinical Research in Canada
The Clinical Research Association of Canada presents Medical Cannabis in Canada
With the support of Access-Pharma Group – Montreal
December 8, 2016 from 6:00 PM
Hilton Hampton Inn et Suites – Montréal (Dorval)
1900, route Transcanadienne, Dorval, QC H9P 2N4
(Service road South, make U-turn at Boul.des Sources)
Admission: Early birds: $75, At the Door: $85, Students: $50 To register click HERE
Registration: from 5:30 PM – 6:00 PM
Networking cocktail: 6:00 PM – 7:00 PM
Presentations: 7:00 PM – 9:00 PM
Discussions: 9:00 PM – 9:30 PM
Medical marijuana or medical cannabis is a growing multi-billion dollar industry. Canada is positioned to be a leader in this industry and in the conduct of medical cannabis research. The medical cannabis plant is currently used for a wide variety of medical conditions and research is underway in Canada showing its therapeutic effects. We are thrilled to have individuals from one of the prominent Licensed Producers MedReleaf to speak about the production of medical cannabinoids as well as the research that they are doing in this area.
MedReleaf is a Canadian Licensed Producer (under Health Canada) and distributor of medical cannabis and the only one that is ISO-9001:2008 certified. They provide more cannabis to patients than any other producer in Canada. They have over 20 ongoing investigative research initiatives, an extensive plant breeding program, and regular patient monitoring and data analysis. MedReleaf is focused on accelerating our understanding of the numerous benefits of medical cannabis, and on validating new treatment options for patients.
1. Discuss the clinical use of medical cannabis including patient demographics and use in the management of chronic pain, depression, anxiety, sleep disorders, PTSD and other conditions and symptoms.
2. Discuss the current Canadian medical cannabis landscape including breaking down the stigma, the role of the licensed producers, regulatory role of Health Canada, education of physicians and patients and the chain from production to sales including Good Manufacturing Practices (GMP).
3. Introduce the research studies conducted at MedReleaf including future research opportunities and next steps for the industry.
4. Review the roles and opportunities of working in this new and emerging industry.
Adam Greenblatt: A cannabis industry pioneer, Adam Greenblatt will share his insights on the medical marijuana landscape including the barriers to safe and legal access to medical cannabis in Quebe. Adam is currently the Head of Quebec Engagement for Tweed (Canada’s largest licensed producer under the ACMPR). He is a co-founder of Santé Cannabis, Montréal’s first cannabinoid clinic and medical cannabis resource centre. Santé Cannabis is the largest collaborator in the Quebec Cannabis Registry, which is a one-of- a-kind pharmacovigilance study into the use of medical cannabis. Adam will share his insights on the medical marijuana landscape in Canada and the unique Quebec perspective.
Shannon O’Hearn: Shannon began working with MedReleaf in 2014, as one of the first members hired to provide patient services. She helped coordinate and oversee development of the Patient Care department, and now supervises a quickly growing team of 15, who service all MedReleaf patients. Shannon is also the Project Manager of Clinical Research, and works closely with other departments within MedReleaf to coordinate project planning, protocol development, regulatory and ethics submissions, and working relationships with external research teams and initiatives sponsored by MedReleaf. She studied Life Sciences at Queen’s University and following that completed a Master’s of Science in Clinical Research Administration.
Angelo Fefekos: Angelo Fefekos is VP Quality Assurance & Compliance at MedReleaf and brings over a decade of experience in quality assurance and laboratory technology to MedReleaf operations. His leadership and technical skills were most recently demonstrated in his role as manager of a team of 40 in the Division of Diagnostic Medical Genetics and Allograft Technologies at Mount Sinai Hospital. There, he successfully implemented Canada’s first, hospital-based manufactured and labeled ‘sterile’ human tissue for transplant use. He also implemented a new workflow that significantly increased patient safety, while standardizing processes and policies. Angelo’s knowledge and experience related to accreditation and regulatory requirements in the production of health products, medical laboratory testing and health services is extensive. As well, he is a Member of the College of Medical Laboratory Technologists of Ontario.